BioAtla Inc
BCAB
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.88M
Close$
$-0.67
138.9% downside
Current Fair Value
138.9% downsideOvervalued by 138.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.88 Million |
|---|---|
| Enterprise Value | $7.20 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-50.5 |
| Beta | 0.76 |
| Outstanding Shares | 1,660,586 |
Return
| Return on Equity | 25.75% |
|---|---|
| Return on Assets | -98.17% |
| Return on Invested Capital | 264.01% |
Valuation & Multiples
| P/E Ratio | -0.07 |
|---|---|
| PEG | 0.07 |
| Price to Sales | 0.35 |
| Price to Book Ratio | -0.08 |
| Enterprise Value to Revenue | 0.85 |
| Enterprise Value to EBIT | -0.24 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.81 |
| Debt to Equity | -0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-8.50
Average shareholder expectationRevenue Estimate
$6.50 M
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-7.00
Average shareholder expectationRevenue Estimate
$5.59 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 6.51%▼ 13.97% |
|---|---|
| Total Invested | $447,645▼ 81.87% |
| Investors Holding | 1▼ 35.00% |
ESG Score
No data
About BioAtla Inc
36 employeesBioAtla® is a San Diego biotech company that develops novel monoclonal antibody and cell based therapeutics using our proprietary Conditionally Active Biologics™ (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!™) platforms...